mitoxantrone + cyclophosphamide + mercaptopurine + vinblastine

This is a combination chemotherapy regimen consisting of four cytotoxic agents: mitoxantrone, cyclophosphamide, mercaptopurine, and vinblastine. Each of these drugs has a distinct mechanism of action: - **Mitoxantrone** is an anthracycline antineoplastic agent that acts primarily by inhibiting topoisomerase II, disrupting DNA synthesis and repair, leading to cell death[1][3][5][7][9]. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA, preventing replication and transcription, resulting in apoptosis[2][4][6][8]. - **Mercaptopurine** (6-mercaptopurine) is a purine analog that interferes with DNA and RNA synthesis by inhibiting the synthesis of purine nucleotides, thus preventing cell proliferation. - **Vinblastine** is a vinca alkaloid that inhibits microtubule formation in mitotic spindle, arresting cell division in metaphase. This combination would be expected to offer synergistic cytotoxic activity against rapidly dividing cancer cells. While combinations involving mitoxantrone and cyclophosphamide are documented for leukemia and lymphoma, and vinblastine and mercaptopurine are standard agents in various hematological malignancies, there is no widely recognized regimen specifically combining all four agents. The combination is experimental and may be considered for certain aggressive or relapsed hematologic cancers.